Summary of evidence search and selection.

Slides:

Advertisements

Similar presentations

Abetimus Sodium (LJP 394) a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene.

Advertisements

SLE and Kidney Disease in 2014 GERALD APPEL, MD GERALD APPEL, MD Professor of Clinical Medicine Columbia University –College of Professor of Clinical Medicine.

Treatment of Vasculitis: immunesuppressives and biologics

Tuesday Clinical Case Conference Zae Kim. Therapy of ANCA-Associated Small Vessel Vasculitis.

Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.

Treatment of LN An European perspective Frédéric A. HOUSSIAU Department of Rheumatology Cliniques universitaires Saint-Luc LOUVAIN Medical School XXXV.

Anti-rheumatic Drugs In Pregnancy And Breastfeeding

A NEW LOOK AT RA Interactive Hot Topics Series

Randomized Controlled Trials of Methotrexate & Mycophenolate in MG

Lupus Nephritis Treatment

Treatment of primary FSGS

Management of Myositis-Related Interstitial Lung Disease

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for.

Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation Takahiro Oto, MD, Mikio Okazaki, MD, Ken Takata, MD, Moritoki Egi, MD, Masaomi.

EULAR Lupus Nephritis Trials Network Study Group 2017

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

RUSSELL H. WIESNER, M. D. , JURGEN LUDWIG, M. D. , RUUD A. F. KROM, M

Nat. Rev. Nephrol. doi: /nrneph

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD,

Figure 4 Proposed therapy scheme for anti-LGI1 encephalitis

Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.

David J. Tunnicliffe, Suetonia C. Palmer

Nat. Rev. Rheumatol. doi: /nrrheum

Fnu Nutan, Alex G. Ortega-Loayza

Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer,

Leflunomide as adjuvant treatment of dermatomyositis

EULAR Lupus Nephritis Trials Network Study Group

Discussion on spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression Ulf Peter Neumann, Peter Neuhaus Gastroenterology

Biosimilars and biologics – What does personalisation mean for you?

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Tac vs Cyc Non DM Pt Post RTx

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

A B Anti-SRP-Myopathy Non-severe Severe*

Consolidated Standards of Reporting Trials diagram.

Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center Jan Groetzner, MD, Bruno Reichart, MD, Ulrich Roemer, MD, Stefanie.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Figure 1 Relapse and rituximab historyThe figure shows rituximab (RTX) treatment history as well as relapse history for 100 days prior to the first RTX.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic.

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Study schemas. Study schemas. Upper panel: single-ascending dose study. Subjects with mild, stable systemic lupus erythematosus (SLE) were randomised to.

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.

Suggested treatment algorithm for resistant lupus nephritis

The effect of purified IgG from healthy controls or patients with lupus nephritis on tyrosine phosphorylation in podocytes at two different IgG concentrations.

Tyrosine phosphorylation of proteins in podocyte lysates following exposure to healthy or lupus nephritis plasma. Tyrosine phosphorylation of proteins.

PRISMA flow diagram for selection of RCTs from leading sports medicine journals for the publication years 2005 and 2015. PRISMA, Preferred Reporting Items.

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG.

Impact of skin damage on health-related quality of life.

Methotrexate and azathioprine in severe atopic dermatitis: A 5-year follow up study of a randomised controlled trial L.A.A. Gerbens, S.A.S Hamann, M.W.D.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Monitoring of DMARDS and use in pregnancy.

Mean change from baseline over time in BILAG score,

Current standard of care treatment protocols for LN induction therapy.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

The most common pitfalls in lupus clinical trials The inner circle lists the most common pitfalls that have hindered the success of lupus clinical trials.

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

ANCA-Associated Vasculitis: Core Curriculum 2020

Volume 77, Issue 2, Pages (January 2010)

(A–E) demonstrate a kidney biopsy from a patient with lupus nephritis (LN) class V. Representative micrographs: (A), an inflammatory infiltrate with T.

Presentation transcript:

Summary of evidence search and selection. Summary of evidence search and selection. A total of 19 immunosuppressants or biologicals alone or in combination were involved in our analyses: intravenous CYC (0.5–1 g/m2 body surface area monthly) (21 trials), AZA (1–4 mg/kg/day) (12 trials), MMF (500–3000 mg/day) (12 trials), TAC (0.05–0.1 mg/kg/day) (four trials), oral CYC (1–4 mg/kg/day) (two trials), CSA (1–5 mg/kg/day) (five trials), MTX (7.5–20 mg/week) (three trials), RTX (1 g/day) (two trials), LD belimumab (1 mg/kg) (four trials), MD belimumab (4 mg/kg) (one trial), HD belimumab (10 mg/kg) (five trials), SC belimumab (200 mg/week) (one trial), LEF (1 mg/kg/day) (one trial), chloroquine (150 mg/day) (one trial), AZA+GC (one trial), MMF+TAC (two trials), intravenous CYC+MMF (one trial), CYC-AZA (two trials) and AZA+CYC (one trial). AZA, azathioprine; CSA, cyclosporine; CYC-AZA, CYC followed by AZA; CYC, cyclophosphamide; GC, glucocorticoid; HD, high dose; LD, low dose; LEF, leflunomide; MD, moderate dose; MMF, mycophenolate mofetil; MTX, methotrexate; RCT, randomised controlled trial; RTX, rituximab; SC, subcutaneous; TAC, tacrolimus, NM, neurological manifestations; LN, lupus nephritis Jingru Tian et al. Lupus Sci Med 2018;5:e000253 ©2018 by Lupus Foundation of America